Rare Sugars: Metabolic Effects and Mechanisms of Action: A Scoping Review

What this review tells formulators

If you are evaluating rare sugars for a reformulation, the first thing to know is this: D-allulose and D-tagatose are the two ingredients with the most human data behind them. The scoping review groups their potential health benefits into three areas: glycemic control, body composition, and cardiovascular disease.

Background: why rare sugars matter

Rare sugars are exactly what the name says. They occur in tiny amounts in nature. Most formulators know them as low-calorie sweeteners, but this review focuses on something else: what happens after you eat them, not just how sweet they taste.

D-allulose appears in the review under the abbreviation PSI, a reference to its old name D-psicose. D-tagatose is listed as TAG. The two are often discussed together, but the evidence for each should be considered separately.

What the study did

This is a scoping review, not a meta-analysis. The team mapped the available research on rare sugars, their metabolic effects, and the mechanisms behind those effects. Then they sorted the human trial evidence into major health themes.

The result is a practical map for formulators who need to know where the evidence is solid and where it is still forming.

Key findings from the human trials

The clearest human evidence points to glycemic control. When D-allulose or D-tagatose is consumed together with carbohydrate, postprandial blood glucose elevation is lower in people with hyperglycemia. That matters for products that combine rare sugars with digestible carbs.

The body composition data comes from a trial with 14 g per day of D-allulose. The changes were modest but significant.

Benefit category	Human evidence in the review
Glycemic control	D-allulose and D-tagatose reduce the glucose rise after carbohydrate intake in people with hyperglycemia.
Body composition	14 g/day D-allulose produced a modest but significant drop in BMI (–0.38 kg/m²) and body fat percentage (–0.74%).
Cardiovascular disease	Identified as one of the three major benefit areas in the review.

That table is short because the review’s conclusions are not a pile of exaggerated claims. The effects are real, but they are not dramatic.

What it means for manufacturers

Pair rare sugars with carbohydrates. The postprandial glucose benefit depends on co-ingestion. A bar, beverage, or bakery item that contains both digestible starch or sugar and a rare sugar gives the ingredient a chance to do its job. A zero-carb product does not.

Treat the body composition numbers as directional. A 0.38 kg/m² BMI change and a 0.74% body fat change are not a weight-loss claim. They are evidence of a metabolic effect worth exploring in a product concept, not a reason to market rare sugars as fat burners.

For ingredient buyers, ask for the specific form and dose used in the trial. D-allulose at 14 g per day is a meaningful dose in a food product. Know your serving size and whether that dose is realistic in your application.

FAQ

Are D-allulose and D-tagatose the same?

No. They are different rare sugars, even though both appear in the same review and have overlapping health benefits.

Do rare sugars lower blood sugar on their own?

The evidence in this review shows a blunting effect when they are eaten with carbohydrate. The same effect would not necessarily appear if they are consumed alone.

Is 14 g per day a lot?

It depends on the product. Fourteen grams of D-allulose is achievable in a serving of a beverage, a sweet sauce, or a few portions of a formulated food. But it is not a sprinkle-level dose.

Closing

Rare sugars are not a magic solution. The evidence says D-allulose and D-tagatose can help control postprandial glucose when paired with carbs in people with hyperglycemia, and D-allulose at 14 g/day has a modest effect on body composition. Those are useful facts for product development. The next step is to test your specific matrix and dose.